Taro Pharmaceutical Industries Ltd Stock News

TheStreet lowered shares of Taro Pharmaceutical Industries (NYSE:TARO) from a c rating to a d+ rating in a report released on Wednesday, TheStreetRatingsTable reports. Several other research firms have also commented on TARO. HC Wainwright lifted their price target on shares of Taro Pharmaceutical Industries from $80.00 to $82.00 and gave the company a buy [] The post Taro Pharmaceutical Industries (NYSE:TARO) Downgraded by TheStreet appeared first on ETF Daily News .

Taro Pharmaceutical Industries (TARO) shares closed today at 0.6% above its 52 week low of $52.61, giving the company a market cap of $1B. The stock is currently down 27.8% year-to-date, down 22.7% over the past 12 months, and down 43.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 23.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -426.9% The company's stock price performance over the past 12 months lags the peer average by -299.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Taro Pharmaceutical Industries (TARO) shares closed today at 0.7% above its 52 week low of $52.61, giving the company a market cap of $2B. The stock is currently down 25.7% year-to-date, down 18.4% over the past 12 months, and down 39.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 18.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -385.9% The company's stock price performance over the past 12 months lags the peer average by -245.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Veriti Management LLC purchased a new position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) in the third quarter, Holdings Channel.com reports. The fund purchased 3,357 shares of the companys stock, valued at approximately $214,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tudor Investment []

Taro (TARO) delivered earnings and revenue surprises of -35.29% and -13.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE SECOND QUARTER RESULTS ON OCTOBER 28, 2021

Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE FIRST QUARTER RESULTS ON JULY 27, 2021

Taro Pharmaceutical Industries (TARO) has been struggling lately, but the selling pressure may be coming to an end soon.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2021

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Provides Results for the Year Ended March 31, 2021